Related Experiment Video

Updated: Jul 11, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Evolving role of novel targeted agents in renal cell carcinoma

Thomas E Hutson1, Robert A Figlin

  • 1Baylor Sammons Cancer Center, U.S. Oncology Research Network Dallas, Texas, USA.

Oncology (Williston Park, N.Y.)
|October 12, 2007
PubMed

Insights

Novel targeted therapies targeting the HIF/VEGF and mTOR pathways have significantly improved outcomes for metastatic renal cell carcinoma (RCC). Ongoing trials continue to define the optimal use of these agents and new drugs in RCC treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (RCC) treatment has evolved significantly.
  • Advances in understanding RCC biology have led to novel targeted therapies.

Purpose of the Study:

  • To review the impact of novel targeted agents on metastatic RCC.
  • To discuss the role of the hypoxia-inducible factor (HIF)/vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways in RCC treatment.

Main Methods:

  • Review of randomized trials and clinical development of targeted agents.
  • Inhibition of key tumorigenic pathways like HIF/VEGF and mTOR.

Main Results:

  • Agents like sunitinib, sorafenib, bevacizumab/interferon alfa, and temsirolimus have improved clinical outcomes.
  • These drugs target specific molecular pathways implicated in RCC growth.

Conclusions:

  • Targeted therapies have altered the natural history of metastatic RCC.
  • Combinations and sequences of agents are under investigation.
  • New multitargeted tyrosine kinase inhibitors and mTOR inhibitors are in development.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...